SureTrader
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 38
Posts 28,376
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Yellen Flags Risks To Outlook That Could Delay Rate Rises
Federal Reserve Chairwoman Janet Yellen flagged risks to the economic outlook that could delay the central bank's plans for raising short-term interest rates, in her semiannual testimony to Congress on U.S. monetary policy.
More Top Equities Stories Of The Day
Star Wars' Is the Force Behind Strong Hasbro Sales -- Update
Andreessen Horowitz Sells Some Lyft Shares to Prince Al-Waleed
Peabody to Draw Down Rest of Revolving Loan
U.S. Judge Questions Regulators on MetLife Designation
Panel Recommends FDA Approval of Remicade Knockoff
Time Warner Sees Strong Subscriber Gains
Ex-J.P. Morgan Executive Fined $1 Million Over London Whale Trades -- Update
Anadarko Slashes Dividend By 81% -- 2nd Update
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 72084 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist